Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AOTI, Inc. ( (GB:AOTI) ) has shared an announcement.
AOTI, Inc. reported preliminary 2025 results showing about 14% revenue growth to roughly $66.5 million and an adjusted EBITDA margin in line with market expectations, with net debt of around $6.5 million remaining better than forecast despite higher receivables. Management said recent restructuring and operational changes are improving sales productivity, leaving the business well positioned to accelerate growth as U.S. healthcare headwinds ease and it awaits a key CMS coverage decision.
The company is grappling with prolonged reimbursement disputes with Arizona Medicaid, where denied payments have pushed receivables to $15.6 million and forced AOTI to stop taking new Arizona Medicaid patients from 1 April 2026, despite the state contributing about $9.2 million of revenue in 2025. While arbitration has secured some back payments, the ongoing uncertainty could still alter final 2025 results, underscoring both the company’s exposure to U.S. reimbursement risk and the importance of diversifying growth across other payers and geographies.
The most recent analyst rating on (GB:AOTI) stock is a Hold with a £44.00 price target. To see the full list of analyst forecasts on AOTI, Inc. stock, see the GB:AOTI Stock Forecast page.
Spark’s Take on GB:AOTI Stock
According to Spark, TipRanks’ AI Analyst, GB:AOTI is a Neutral.
The score is primarily constrained by ongoing losses and weak cash flow sustainability despite strong revenue growth and improved margins. Technicals are supportive but show signs of being stretched, and valuation is pressured by negative earnings with no dividend support.
To see Spark’s full report on GB:AOTI stock, click here.
More about AOTI, Inc.
AOTI, Inc. is a medical technology company based in Oceanside, California and Galway, Ireland, specializing in non-invasive therapies for severe and chronic wounds. Its flagship Topical Wound Oxygen (TWO2) therapy is used at home to treat diabetic foot ulcers, backed by randomized trials and real-world data showing significant reductions in hospitalizations and amputations, and holds regulatory clearances and positive coverage decisions across major global markets.
Average Trading Volume: 63,980
Technical Sentiment Signal: Sell
Current Market Cap: £41.48M
Find detailed analytics on AOTI stock on TipRanks’ Stock Analysis page.